CeriBell (NASDAQ:CBLL) Given Average Rating of “Buy” by Analysts

CeriBell (NASDAQ:CBLL) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $32.60.

CBLL has been the subject of a number of analyst reports. Bank of America initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 price objective for the company. William Blair initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group increased their price objective on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 9th. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company.

CeriBell Stock Up 0.8 %

NASDAQ:CBLL opened at $22.15 on Thursday. CeriBell has a fifty-two week low of $18.69 and a fifty-two week high of $32.75. The company’s 50 day moving average is $23.74.

Hedge Funds Weigh In On CeriBell

A number of institutional investors have recently added to or reduced their stakes in CBLL. Rhumbline Advisers bought a new position in CeriBell in the fourth quarter worth $320,000. Bank of New York Mellon Corp bought a new position in CeriBell in the fourth quarter worth $628,000. Charles Schwab Investment Management Inc. bought a new position in CeriBell in the fourth quarter worth $2,500,000. PNC Financial Services Group Inc. bought a new position in CeriBell in the fourth quarter worth $47,000. Finally, Vanguard Group Inc. bought a new position in CeriBell in the fourth quarter worth $18,015,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.